MENJUGATE LIQUID SUSPENSION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

MENINGOCOCCAL GROUP C OLIGOSACCHARIDE; CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN

Prieinama:

GLAXOSMITHKLINE INC

ATC kodas:

J07AH

INN (Tarptautinis Pavadinimas):

MENINGOCOCCAL VACCINES

Dozė:

10MCG; 25MCG

Vaisto forma:

SUSPENSION

Sudėtis:

MENINGOCOCCAL GROUP C OLIGOSACCHARIDE 10MCG; CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN 25MCG

Vartojimo būdas:

INTRAMUSCULAR

Vienetai pakuotėje:

0.5ML

Recepto tipas:

Schedule D

Gydymo sritis:

TOXOIDS

Produkto santrauka:

Active ingredient group (AIG) number: 0243741003; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2015-12-16

Prekės savybės

_ _
_Page 1 of 25_
PRODUCT MONOGRAPH
MENJUGATE
LIQUID
10 micrograms suspension for injection
Meningococcal Group C Conjugate Vaccine
House Standard
Suspension for Injection
Active Immunizing Agent
ATC Code J07A H
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
DATE OF INITIAL APPROVAL:
June 17, 2015
DATE OF REVISION:
June 28, 2019
SUBMISSION CONTROL #: 226119
_ _
_©_
_2019 GSK group of companies or its licensor _
Trademarks are owned by or licensed to the GSK group of companies
_PENTACEL is a trademark of Sanofi Pasteur Limited. _
_ _
_Page 2 of 25_
_ _
_Page 3 of 25_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 4
SUMMARY PRODUCT INFORMATION
.......................................................................
4
INDICATIONS AND CLINICAL USE
.............................................................................
4
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
6
DRUG INTERACTIONS
.................................................................................................
11
DOSAGE AND ADMINISTRATION
.............................................................................
12
OVERDOSAGE
...............................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 14
STORAGE AND STABILITY
.........................................................................................
14
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 14
PART II: SCIENTIFIC INFORMATION
...............................................................................
16
PHARM